← Back

TransMedics Group Inc

82.99-27.2%1Y · USD

TransMedics Group, Inc. is a commercial-stage medical technology company focused on transforming organ transplant therapy for patients with end-stage organ failure in the United States and internationally. The company offers the Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that uses proprietary technology to replicate near-physiologic conditions for donor organs outside the human body. Its OCS products include OCS LUNG for preserving standard criteria donor lungs for double-lung transplantation, OCS Heart for preserving DBD donor hearts unsuitable for cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts, and OCS Liver for preserving DBD and DCD donor livers. The company also developed a national OCS program, a turnkey solution for outsourced organ retrieval, and provides OCS organ management and logistics services, including aviation and ground transportation and other coordination activities. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.

Country
Price · split & dividend adjusted
News & notes moving TMDX
United States
TMDX▼2

TransMedics Stock Dips After Q2 Earnings Miss and Margin Contraction

TransMedics Group shares fell 7.8% in after-market trading after the company reported second-quarter 2026 earnings per share of 44 cents, down 52.2% year over year and missing the Zacks Consensus Estimate by 12%. Revenue rose 20.7% to $189.9 million, beating estimates by 3.1%, driven by a 15.7% increase in net product revenues to $111.2 million and a 28.6% jump in service revenues to $78.8 million, which represented roughly 41% of total revenues. Adjusted operating profit declined 29.5% to $25.8 million, and the adjusted operating margin contracted 960 basis points to 13.6%, as research and development expenses nearly doubled to $31.6 million. The company raised the lower end of its 2026 revenue guidance to a range of $737 million to $757 million, implying 22% to 25% growth, but expects adjusted operating margin between 12.5% and 14%, below its prior expectation of approximately 16%, due to accelerated OCS Kidney investments.
TMDX ▼
TMDX · Capital · Negative Q2 EPS miss and margin contraction due to higher R&D and OCS Kidney investments.
Read original ↗
Zacks Investment Research·61dRead more →
TMDX▲

TransMedics Group Invests in PAD Aviation to Expand Organ Care System into Europe

TransMedics Group announced a strategic investment in Germany-based private aviation operator PAD Aviation to support the expansion of its Organ Care System National OCS Program into Europe. The partnership aims to increase adoption of the company's OCS perfusion technology and establish a dedicated pan-European air and ground logistics network for organ transportation across the European Union. TransMedics expects the collaboration to improve access to donor organs, streamline transplant logistics, and increase transplant opportunities for patients throughout Europe. Separately, Evercore ISI analyst Daniel Markowitz lowered the price target on TransMedics to $90 from $100 while maintaining an Outperform rating, citing stable procedure volumes and capital spending trends across the MedTech sector.
TMDX ▲
TMDX · Demand · Positive Investment in PAD Aviation aims to expand OCS program into Europe, increasing adoption and transplant opportunities.
TMDX · Capital · Negative Evercore ISI analyst lowered price target to $90 from $100, citing stable procedure volumes and capital spending trends.
PAD Aviation service GmbH · Demand · Positive Strategic investment from TransMedics will expand PAD Aviation's role in organ transportation logistics across Europe.
Read original ↗
Insider Monkey·89dRead more →
TMDX▲

TransMedics completes strategic investment in PAD Aviation

TransMedics Group has completed its strategic investment in Germany-based private aviation operator PAD Aviation. The investment lays the foundation for TransMedics to establish a dedicated pan-European organ transplant air and ground logistics network, replicating its US OCS NOP model to expand adoption of its perfusion technology and increase donor organ utilization across the European Union. PAD Aviation operates a modern fleet including nine Embraer Phenom 300 aircraft from its 24/7 hub in Paderborn, Germany, and holds a valid EASA Air Operator Certificate. TransMedics President and CEO Waleed Hassanein stated that the partnership creates a significant opportunity to save more European transplant patients.
TMDX ▲
TMDX · Demand · Positive Investment enables pan-European logistics network to expand adoption of OCS perfusion technology and increase donor organ utilization.
PAD Aviation service GmbH · Capital · Positive Receives strategic investment from TransMedics, providing capital and partnership for aviation operations.
Read original ↗
PR Newswire·91dRead more →
TMDX▲2

TransMedics Group Could Dominate Organ Transplant Logistics in 10 Years

TransMedics Group is building a vertically integrated organ transplant logistics network that could make it the dominant infrastructure provider in the U.S. and Europe within a decade. The company's Organ Care System keeps donor organs alive outside the body, and its National OCS Program operates a fleet of 22 aircraft with clinical teams to transport organs. A kidney preservation program in development would dramatically expand its addressable market, given over 90,000 Americans are waiting for kidney transplants. TransMedics is also scaling in Europe through an investment in German aviation operator PAD Aviation and a ground transport collaboration in Italy. While heavy spending on expansion compressed margins and contributed to a 45% share price decline over six months, revenue still grew 21% year over year in the first quarter of 2026.
TMDX ▲
TMDX · Demand · Positive Kidney preservation program expands addressable market to over 90,000 waiting patients, and revenue grew 21% YoY.
Read original ↗
The Motley Fool·94dRead more →
TMDX

TransMedics Stock Retained on Strength in OCS Technology Despite Margin Pressure

TransMedics Group remains a hold-rated stock as its Organ Care System technology drives adoption and first-quarter 2026 results show solid case volume growth, though gross margin pressure persists. The company's OCS is the only FDA-approved portable platform offering warm perfusion for heart, lung, and liver transplants, positioning it as a leader in the multi-billion-dollar transplant market. TransMedics is advancing next-generation OCS systems and expanding into kidney transplantation, with a U.S. IDE submission targeted for early 2027. First-quarter gross margin fell 331 basis points year over year to approximately 58%, weighed by investments in clinical programs and lower-margin logistics revenue. The Zacks Consensus Estimate for 2026 earnings has been revised down by 3 cents to $1.87 per share over the past 30 days.
TMDX
TMDX · Technology · Neutral OCS technology drives adoption and next-gen systems advancing, but margin pressure and earnings estimate cut create mixed outlook
Read original ↗
Zacks Investment Research·97dRead more →
© 2026 MarketDXAsset